<DOC>
	<DOCNO>NCT01494506</DOCNO>
	<brief_summary>The study open label , randomize phase 3 study MM-398 without 5-Fluorouracil ( 5-FU ) Leucovorin ( also know folinic acid ) , versus 5-FU leucovorin metastatic pancreatic cancer patient progress prior gemcitabine base therapy .</brief_summary>
	<brief_title>Study MM-398 With Without 5-FU/LV , Versus 5-FU/LV Patients With Metastatic Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma exocrine pancreas Metastatic disease Documented disease progression prior gemcitabine base therapy KPS &gt; /= 70 Adequate bone marrow function Adequate hepatic function Adequate renal function Active CNS metastasis Clinically significant GI disorder Severe arterial thromboembolic event le 6 month inclusion NYHA Class III IV congestive heart failure , ventricular arrhythmia uncontrolled blood pressure Active infection uncontrolled fever Pregnant breast feeding patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Pancreatic cancer</keyword>
	<keyword>MM-398</keyword>
	<keyword>PEP02</keyword>
	<keyword>Metastatic pancreatic cancer</keyword>
	<keyword>Gemcitabine refractory pancreatic cancer</keyword>
	<keyword>Second line pancreatic cancer treatment</keyword>
	<keyword>Pancreatic cancer post gemcitabine therapy</keyword>
</DOC>